RBC Capital analyst Luca Issi raised the firm’s price target on Moderna to $135 from $125 and keeps an Outperform rating on the shares. The company’s Q1 earnings beat was driven mainly by lower operating expenditure, and with RSV vaccine approval remaining on track for end of next week, RBC remains positive on a market that is “off an impressive start”, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
